Dietary intakes of flavan-3-ols and cardiometabolic health: systematic review and meta-analysis of randomized trials and prospective cohort studies

Gowri Raman, Esther E Avendano, Siyu Chen, Jiaqi Wang, Julia Matson, Bridget Gayer, Janet A Novotny, Aedín Cassidy, Gowri Raman, Esther E Avendano, Siyu Chen, Jiaqi Wang, Julia Matson, Bridget Gayer, Janet A Novotny, Aedín Cassidy

Abstract

Background: Although available data suggest that some dietary flavan-3-ol sources reduce cardiometabolic risk, to our knowledge no review has systematically synthesized their specific contribution.

Objective: We aimed to examine, for the first time, if there is consistent evidence that higher flavan-3-ol intake, irrespective of dietary source, reduces cardiometabolic risk.

Methods: MEDLINE, Cochrane Central, and Commonwealth Agricultural Bureau abstracts were searched for prospective cohorts and randomized controlled trials (RCTs) published from 1946 to March 2019 on flavan-3-ol intake and cardiovascular disease (CVD) risk. Random-effects models meta-analysis was used. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach assessed the strength of evidence.

Results: Of 15 prospective cohorts (23 publications), 4 found highest compared with lowest habitual intakes of flavan-3-ols were associated with a 13% reduction in risk of CVD mortality and 2 found a 19% reduction in risk of chronic heart disease (CHD) incidence. Highest compared with lowest habitual intakes of monomers were associated with a reduction in risk of type 2 diabetes mellitus (T2DM) (n = 5) and stroke (n = 4) (10% and 18%, respectively). No association was found for hypertension. Of 156 RCTs, flavan-3-ol intervention resulted in significant improvements in acute/chronic flow-mediated dilation (FMD), systolic (SBP) and diastolic blood pressure (DBP), total cholesterol (TC), LDL and HDL cholesterol, triglycerides (TGs), hemoglobin A1c (HbA1c), and homeostasis model assessment of insulin resistance (HOMA-IR). All analyses, except HbA1c, were associated with moderate/high heterogeneity. When analyses were limited to good methodological quality studies, improvements in TC, HDL cholesterol, SBP, DBP, HOMA-IR, and acute/chronic FMD remained significant. In GRADE evaluations, there was moderate evidence in cohort studies that flavan-3-ol and monomer intakes were associated with reduced risk of CVD mortality, CHD, stroke, and T2DM, whereas RCTs reported improved TC, HDL cholesterol, SBP, and HOMA-IR.

Conclusions: Available evidence supports a beneficial effect of flavan-3-ol intake on cardiometabolic outcomes, but there was considerable heterogeneity in the meta-analysis. Future research should focus on an integrated intake/biomarker approach in cohorts and high-quality dose-response RCTs. This review was registered at www.crd.york.ac.uk/PROSPERO/ as CRD42018035782.

Keywords: blood pressure; cardiovascular; diabetes; flavan-3-ols; flavonoids.

Copyright © American Society for Nutrition 2019.

Figures

FIGURE 1
FIGURE 1
Study flow diagram depicting the review process. CAB, Commonwealth Agricultural Bureau; RCT, randomized controlled trial.
FIGURE 2
FIGURE 2
The effect of flavan-3-ols on cardiometabolic health outcomes from prospective cohort studies. Data reported are RRs and 95% CIs for a fully adjusted random-effects meta-analysis model for each outcome. *Hypertension outcome included men and women subpopulations from the same cohort from 1 article that reported total flavan-3-ol intake and blood pressure. CHD, chronic heart disease; CVD, cardiovascular disease.
FIGURE 3
FIGURE 3
The effect of flavan-3-ols on cardiometabolic risk biomarkers from RCTs. Data estimates are from meta-analysis of the net change and 95% CI for each outcome. DBP, diastolic blood pressure; FBG, fasting blood glucose; FMD, flow-mediated dilation; HbA1c, hemoglobin A1c; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; RCT, randomized controlled trial; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.

References

    1. Cassidy A, Minihane AM. The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids. Am J Clin Nutr. 2017;105:10–22.
    1. Del RD, Rodriguez-Mateos A, Spencer JP, Tognolini M, Borges G, Crozier A. Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal. 2013;18:1818–92.
    1. Perez-Vizcaino F, Fraga CG. Research trends in flavonoids and health. Arch Biochem Biophys. 2018;646:107–12.
    1. Rodriguez-Mateos A, Vauzour D, Krueger CG, Shanmuganayagam D, Reed J, Calani L, Mena P, Del Rio D, Crozier A. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update. Arch Toxicol. 2014;88:1803–53.
    1. Greyling A, Ras RT, Zock PL, Lorenz M, Hopman MT, Thijssen DH, Draijer R. The effect of black tea on blood pressure: a systematic review with meta-analysis of randomized controlled trials. PLoS One. 2014;9:e103247.
    1. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, Ryder JJ, Hall WL, Cassidy A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:38–50.
    1. Hooper L, Kay C, Abdelhamid A, Kroon PA, Cohn JS, Rimm EB, Cassidy A. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr. 2012;95:740–51.
    1. Buitrago-Lopez A, Sanderson J, Johnson L, Warnakula S, Wood A, Di AE, Franco OH. Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. BMJ. 2011;343:d4488.
    1. Larsson SC, Virtamo J, Wolk A. Chocolate consumption and risk of stroke: a prospective cohort of men and meta-analysis. Neurology. 2012;79:1223–9.
    1. Ried K, Fakler P, Stocks NP. Effect of cocoa on blood pressure. Cochrane Database Syst Rev. 2017;4:CD008893.
    1. Shrime MG, Bauer SR, McDonald AC, Chowdhury NH, Coltart CE, Ding EL. Flavonoid-rich cocoa consumption affects multiple cardiovascular risk factors in a meta-analysis of short-term studies. J Nutr. 2011;141:1982–8.
    1. Zhang C, Qin YY, Wei X, Yu FF, Zhou YH, He J. Tea consumption and risk of cardiovascular outcomes and total mortality: a systematic review and meta-analysis of prospective observational studies. Eur J Epidemiol. 2015;30:103–13.
    1. Zhao Y, Asimi S, Wu K, Zheng J, Li D. Black tea consumption and serum cholesterol concentration: systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2015;34:612–19.
    1. Raman G, Shams-White M, Avendano EE, Chen F, Novotny JA, Cassidy A. Dietary intakes of flavan-3-ols and cardiovascular health: a field synopsis using evidence mapping of randomized trials and prospective cohort studies. Syst Rev. 2018;7:100.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9, W64.
    1. Bhagwat S, Haytowitz DB. USDA's Database for the Proanthocyanidin Content of Selected Foods. Release 2. Beltsville, MD: USDA, Agricultural Research Service Nutrient Data Laboratory; 2015. Available from:.
    1. Bhagwat S, Haytowitz DB. USDA Database for the Flavonoid Content of Selected Foods, Release 3.2. [Internet] Beltsville, MD: USDA, Agricultural Research Service Nutrient Data Laboratory; 2015. Available from: .
    1. Neveu V, Perez-Jiménez J, Vos F, Crespy V, du Chaffaut L, Mennen L, Knox C, Eisner R, Cruz J, Wishart D et al. .. Phenol-Explorer: an online comprehensive database on polyphenol contents in foods. Database. 2010:bap024.
    1. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
    1. Lichtenstein AH, Yetley EA, Lau J. Application of systematic review methodology to the field of nutrition. J Nutr. 2008;138:2297–306.
    1. Viswanathan M, Patnode CD, Berkman ND, Bass EB, Chang S, Hartling L, Murad MH, Treadwell JR, Kane RL. Recommendations for assessing the risk of bias in systematic reviews of health-care interventions. J Clin Epidemiol. 2018;97:26–34.
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
    1. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D et al. .. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
    1. Arts IC, Hollman PC, Feskens EJ, Bueno de Mesquita HB, Kromhout D. Catechin intake might explain the inverse relation between tea consumption and ischemic heart disease: the Zutphen Elderly Study. Am J Clin Nutr. 2001;74:227–32.
    1. Arts IC, Jacobs DR Jr, Harnack LJ, Gross M, Folsom AR. Dietary catechins in relation to coronary heart disease death among postmenopausal women. Epidemiology. 2001;12:668–75.
    1. Cassidy A, O'Reilly EJ, Kay C, Sampson L, Franz M, Forman JP, Curhan G, Rimm EB. Habitual intake of flavonoid subclasses and incident hypertension in adults. Am J Clin Nutr. 2011;93:338–47.
    1. Cassidy A, Mukamal KJ, Liu L, Franz M, Eliassen AH, Rimm EB. High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. Circulation. 2013;127:188–96.
    1. Dower JI, Geleijnse JM, Hollman PC, Soedamah-Muthu SS, Kromhout D. Dietary epicatechin intake and 25-y risk of cardiovascular mortality: the Zutphen Elderly Study. Am J Clin Nutr. 2016;104:58–64.
    1. Goetz ME, Judd SE, Hartman TJ, McClellan W, Anderson A, Vaccarino V. Flavanone intake is inversely associated with risk of incident ischemic stroke in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. J Nutr. 2016;146:2233–43.
    1. Goetz ME, Judd SE, Safford MM, Hartman TJ, McClellan WM, Vaccarino V. Dietary flavonoid intake and incident coronary heart disease: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am J Clin Nutr. 2016;104:1236–44.
    1. Ivey KL, Lewis JR, Prince RL, Hodgson JM. Tea and non-tea flavonol intakes in relation to atherosclerotic vascular disease mortality in older women. Br J Nutr. 2013;110:1648–55.
    1. Jacques PF, Cassidy A, Rogers G, Peterson JJ, Meigs JB, Dwyer JT. Higher dietary flavonol intake is associated with lower incidence of type 2 diabetes. J Nutr. 2013;143:1474–80.
    1. Lajous M, Rossignol E, Fagherazzi G, Perquier F, Scalbert A, Clavel-Chapelon F, Boutron-Ruault MC. Flavonoid intake and incident hypertension in women. Am J Clin Nutr. 2016;103:1091–8.
    1. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr. 2012;95:454–64.
    1. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, Jacobs DR Jr. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr. 2007;85:895–909.
    1. Mursu J, Voutilainen S, Nurmi T, Tuomainen TP, Kurl S, Salonen JT. Flavonoid intake and the risk of ischaemic stroke and CVD mortality in middle-aged Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr. 2008;100:890–5.
    1. Tresserra-Rimbau A, Rimm EB, Medina-Remón A, Martínez-González MA, de la Torre R, Corella D, Salas-Salvadó J, Gómez-Gracia E, Lapetra J, Arós F et al. .. Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study. Nutr Metab Cardiovasc Dis. 2014;24:639–47.
    1. Vogiatzoglou A, Mulligan AA, Bhaniani A, Lentjes MAH, McTaggart A, Luben RN, Heiss C, Kelm M, Merx MW,Spencer JPE et al. .. Associations between flavan-3-ol intake and CVD risk in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk). Free Radic Biol Med. 2015;84:1–10.
    1. Wedick NM, Pan A, Cassidy A, Rimm EB, Sampson L, Rosner B, Willett W, Hu FB, Sun Q, van Dam RM. Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. Am J Clin Nutr. 2012;95:925–33.
    1. Adriouch S, Lampure A, Nechba A, Baudry J, Assmann K, Kesse-Guyot E, Hercberg S, Scalbert A, Touvier M, Fezeu LK. Prospective association between total and specific dietary polyphenol intakes and cardiovascular disease risk in the Nutrinet-Santé French Cohort. Nutrients. 2018;10:E1587.
    1. Grosso G, Stepaniak U, Micek A, Kozela M, Stefler D, Bobak M, Pajak A. Dietary polyphenol intake and risk of type 2 diabetes in the Polish arm of the Health, Alcohol and Psychosocial factors in Eastern Europe (HAPIEE) study. Br J Nutr. 2017;118:60–8.
    1. Grosso G, Stepaniak U, Micek A, Kozela M, Stefler D, Bobak M, Pajak A. Dietary polyphenol intake and risk of hypertension in the Polish arm of the HAPIEE study. Eur J Nutr. 2018;57:1535–44.
    1. Tresserra-Rimbau A, Guasch-Ferré M, Salas-Salvadó J, Toledo E, Corella D, Castañer O, Guo X, Gómez-Gracia E, Lapetra J, Arós F et al. .. Intake of total polyphenols and some classes of polyphenols is inversely associated with diabetes in elderly people at high cardiovascular disease risk. J Nutr. 2016;146:767–77.
    1. Zamora-Ros R, Forouhi NG, Sharp SJ, Gonzalez CA, Buijsse B, Guevara M, van der Schouw YT, Amiano P, Boeing H, Bredsdorff L et al. .. The association between dietary flavonoid and lignan intakes and incident type 2 diabetes in European populations: the EPIC-InterAct study. Diabetes Care. 2013;36:3961–70.
    1. Zamora-Ros R, Forouhi NG, Sharp SJ, Gonzalez CA, Buijsse B, Guevara M, van der Schouw YT, Amiano P, Boeing H, Bredsdorff L et al. .. Dietary intakes of individual flavanols and flavonols are inversely associated with incident type 2 diabetes in European populations. J Nutr. 2014;144:335–43.
    1. Ponzo V, Goitre I, Fadda M, Gambino R, De Francesco A, Soldati L, Gentile L, Magistroni P, Cassader M, Bo S. Dietary flavonoid intake and cardiovascular risk: a population-based cohort study. J Transl Med. 2015;13:218.
    1. Curtis PJ, Sampson M, Potter J, Dhatariya K, Kroon PA, Cassidy A. Chronic ingestion of flavan-3-ols and isoflavones improves insulin sensitivity and lipoprotein status and attenuates estimated 10-year CVD risk in medicated postmenopausal women with type 2 diabetes: a 1-year, double-blind, randomized, controlled trial. Diabetes Care. 2012;35:226–32.
    1. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging. 2010;26:631–40.
    1. Kay CD, Hooper L, Kroon PA, Rimm EB, Cassidy A. Relative impact of flavonoid composition, dose and structure on vascular function: a systematic review of randomised controlled trials of flavonoid-rich food products. Mol Nutr Food Res. 2012;56:1605–16.
    1. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H, Kwik-Uribe C, Schmitz HH, Kelm M. (−)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci U S A. 2006;103:1024–9.
    1. Milenkovic D, Berghe WV, Morand C, Claude S, van de Sandt A, Gorressen S, Monfoulet LE, Chirumamilla CS, Declerck K, Szic KSV et al. .. A systems biology network analysis of nutri(epi)genomic changes in endothelial cells exposed to epicatechin metabolites. Sci Rep. 2018;8:15487.
    1. Claude S, Boby C, Rodriguez-Mateos A, Spencer JP, Gerard N, Morand C, Milenkovic D. Flavanol metabolites reduce monocyte adhesion to endothelial cells through modulation of expression of genes via p38-MAPK and p65-Nf-kB pathways. Mol Nutr Food Res. 2014;58:1016–27.
    1. Jalil AM, Ismail A, Pei CP, Hamid M, Kamaruddin SH. Effects of cocoa extract on glucometabolism, oxidative stress, and antioxidant enzymes in obese-diabetic (Ob-db) rats. J Agric Food Chem. 2008;56:7877–84.
    1. Strat KM, Rowley TJ, Smithson AT, Tessem JS, Hulver MW, Liu D, Davy BM, Davy KP, Neilson AP. Mechanisms by which cocoa flavanols improve metabolic syndrome and related disorders. J Nutr Biochem. 2016;35:1–21.
    1. Fernández-Millán E, Cordero-Herrera I, Ramos S, Escrivá F, Alvarez C, Goya L, Martín MA. Cocoa-rich diet attenuates beta cell mass loss and function in young Zucker diabetic fatty rats by preventing oxidative stress and beta cell apoptosis. Mol Nutr Food Res. 2015;59:820–4.
    1. Sun Q, Wedick NM, Tworoger SS, Pan A, Townsend MK, Cassidy A, Franke AA, Rimm EB, Hu FB, van Dam RM. Urinary excretion of select dietary polyphenol metabolites is associated with a lower risk of type 2 diabetes in proximate but not remote follow-up in a prospective investigation in 2 cohorts of US women. J Nutr. 2015;145:1280–8.
    1. Kim K, Vance TM, Chun OK. Estimated intake and major food sources of flavonoids among US adults: changes between 1999–2002 and 2007–2010 in NHANES. Eur J Nutr. 2016;55:833–43.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit